NAC Dosage: N-Acetylcysteine Amounts Used in Research
NAC has an unusual double life. It is a hospital medicine with decades of use in paracetamol overdose and in chest medicine, and it is a supplement sold in capsules for everything from mood to mucus. Those two lives use different doses and different levels of supervision.
In chronic respiratory research, oral N-acetylcysteine has commonly been studied at 600 mg once or twice daily, with a widely cited trial in chronic obstructive pulmonary disease using 600 mg twice a day. Psychiatric research has often used higher amounts, frequently 2,000 to 2,400 mg per day split into two doses. NAC is a cysteine donor that supports glutathione synthesis, which is the mechanism underlying its established hospital use. There is no established daily requirement, and its regulatory status as a supplement in the United States has been formally disputed by the FDA because it was approved as a drug first.
N-acetylcysteine amounts reported in the research literature
| Use case | Amount reported in sources | What to know |
|---|---|---|
| Chronic obstructive pulmonary disease research | 600 mg twice daily in the PANTHEON trial | Randomised, double-blind, placebo-controlled trial in Chinese patients with COPD over one year. Source |
| Psychiatric and neuropsychiatric research | Commonly 2,000–2,400 mg per day, split | Systematic reviews of NAC in psychiatric disorders describe this range as the typical trial dose. Source |
| Paracetamol (acetaminophen) overdose | Weight-based hospital protocol, intravenous or oral | An emergency treatment administered under medical supervision — not a self-directed use. Source |
| Regulatory status | Disputed as a dietary supplement ingredient in the US | FDA has stated NAC was approved as a drug before marketing as a supplement, while exercising enforcement discretion. Source |
Figures are amounts reported in the cited sources, not a personal recommendation. Your own amount depends on your health, medicines and blood work.
What NAC actually does in the body
Glutathione is the body's principal intracellular antioxidant, and the rate-limiting ingredient for making it is cysteine. NAC is a stable, absorbable form of cysteine, so supplying it gives cells more raw material for glutathione synthesis.
That is the whole mechanism, and it explains the hospital use precisely. In paracetamol overdose, a toxic metabolite depletes liver glutathione; NAC replenishes the supply and prevents liver failure if given early enough. This is one of the clearest antidote stories in medicine.
It also explains why the supplement claims are so sprawling. Glutathione is involved in almost everything, so almost any condition can be argued to be a glutathione problem. Broad mechanistic plausibility is not the same as trial evidence for a specific outcome.
- NAC donates cysteine, the limiting ingredient for glutathione
- Its antidote role in paracetamol overdose is well established
- It also has direct mucolytic effects on airway secretions
- Wide mechanistic reach is why claims outrun the evidence
The respiratory evidence
PANTHEON, published in The Lancet Respiratory Medicine in 2014, randomised patients with chronic obstructive pulmonary disease to 600 mg of NAC twice daily or placebo for a year and reported a reduction in the annual rate of exacerbations in the treatment group.
Earlier trials at lower doses had produced mixed results, which is part of why the twice-daily figure became the reference point rather than 600 mg once a day. Results across the COPD literature are not uniform, and guidelines treat NAC as an adjunct rather than a core therapy.
The mucolytic effect — thinning airway secretions — is separate from the glutathione story and is the older of NAC's two respiratory rationales.
Psychiatric trials use much larger amounts
Research into NAC for conditions including obsessive-compulsive symptoms, trichotillomania, addiction and mood disorders has generally used 2,000 to 2,400 mg a day, split across two doses, over trials lasting three months or longer.
Results in this literature are genuinely mixed. Some trials report benefit, others find no separation from placebo, and sample sizes are often small. Reviews consistently note that the evidence is promising rather than conclusive, and that NAC is not a replacement for established treatment.
Anyone considering NAC for a mental health reason should be doing it alongside care, not instead of it — and the dose gap between the respiratory and psychiatric literature is large enough that copying the wrong one is easy.
The regulatory oddity in the United States
In 2020 and 2021 the FDA took the position that NAC is excluded from the dietary supplement definition because it was approved as a drug before it was marketed as a supplement. The agency later issued guidance describing enforcement discretion while it considered rulemaking.
For a buyer, this means availability may vary by retailer and country, and it means the product is not sitting inside a tidy regulatory category. It does not mean NAC is unsafe; it means the paperwork is contested.
It also underlines a practical point: because NAC is a real drug in hospital settings, taking it should be disclosed to your prescriber the way a medicine would be.
Tolerability and who should be cautious
Oral NAC commonly causes nausea, vomiting, diarrhoea and a sulphurous smell that people find unpleasant. Taking it with food reduces the digestive complaints for most, though it may modestly reduce absorption.
Anaphylactoid reactions — rash, flushing, wheeze, low blood pressure — are documented mainly with intravenous administration in hospital, but asthma is a recognised caution because of the potential for bronchospasm.
NAC has antiplatelet properties and may add to the effect of nitroglycerin on blood pressure, so people on cardiac medicines or anticoagulants should raise it with a prescriber before starting.
What the published studies found
Each entry below links straight to the paper or the health authority page so you can read the original rather than take our word for it.
- Zheng JP, Wen FQ, Bai CX, et al. Twice daily N-acetylcysteine 600 mg for exacerbations of chronic obstructive pulmonary disease (PANTHEON): a randomised, double-blind placebo-controlled trial. Lancet Respir Med. 2014.
Randomised, double-blind, placebo-controlled trial over one year
NAC 600 mg twice daily was associated with a lower annual rate of COPD exacerbations compared with placebo.
- Acetylcysteine — StatPearls. National Center for Biotechnology Information bookshelf.
Clinical reference review
Describes acetylcysteine's established role in paracetamol overdose and as a mucolytic, together with dosing protocols, contraindications and adverse reaction profile.
- US Food and Drug Administration. Policy Regarding N-acetyl-L-cysteine: Guidance for Industry.
Regulatory guidance document
States FDA's position that NAC is excluded from the dietary supplement definition due to prior drug approval, while describing enforcement discretion.
Side effects reported in the literature
Commonly reported
- Nausea and vomiting
- Diarrhoea or abdominal discomfort
- Sulphurous smell and taste
- Headache
Serious, seek medical advice
- Anaphylactoid reactions, documented mainly with intravenous administration
- Bronchospasm in people with asthma
- Additive effects with antiplatelet therapy or nitroglycerin
Summarised from StatPearls — Acetylcysteine. Report anything unexpected to your own doctor or pharmacist.
Interactions to check with a pharmacist
| Medicine or condition | What sources report |
|---|---|
| Nitroglycerin | Combination has been associated with pronounced blood pressure drops and headache. Source |
| Antiplatelet and anticoagulant therapy | NAC has antiplatelet activity; additive bleeding risk is plausible. Source |
| Activated charcoal | Can adsorb oral acetylcysteine, which is why overdose protocols are hospital-run. Source |
| Asthma treatment | Potential for bronchospasm means NAC belongs in the conversation with your team. Source |
This is not a complete interaction list. Check your own medicines with a pharmacist before combining anything.
This page is reference material, not medical advice. Supplements interact with prescription medicines and with each other. Talk to a doctor or pharmacist before starting anything, especially if you are pregnant, breastfeeding, managing a health condition or taking prescription medicine.
Frequently asked questions
How much NAC should you take per day?
It depends entirely on which literature you are reading. Respiratory trials commonly used 600 mg once or twice daily, while psychiatric research typically used 2,000–2,400 mg a day split into two doses. There is no established requirement and NAC is a hospital medicine as well as a supplement, so the dose is a prescriber conversation.
Is 600 mg of NAC enough?
That is the dose used in the PANTHEON COPD trial, taken twice a day. It is well below the amounts used in psychiatric research, so 'enough' depends on the outcome being studied rather than on a universal number.
Should NAC be taken with or without food?
Trials have used both. Taking it with food reduces nausea for most people, at the cost of possibly slightly lower absorption — which is why the sulphur smell and stomach upset are the usual practical deciders.
Why is NAC hard to buy in the US?
The FDA has stated NAC is excluded from the dietary supplement definition because it was approved as a drug first, and issued guidance describing enforcement discretion. Availability therefore varies by retailer rather than by any safety recall.
Does NAC raise glutathione?
NAC supplies cysteine, the rate-limiting ingredient for glutathione synthesis, which is the mechanism behind its use as an antidote in paracetamol overdose. Whether that translates into a measurable benefit for a specific everyday complaint is what individual trials have to answer separately.
Can you take NAC long term?
The COPD trial ran a full year, and psychiatric trials often ran several months, so medium-term data exist. Longer-term supplement use has not been characterised as well, and it should be disclosed to your prescriber like a medicine.
Is NAC safe with asthma?
It needs medical input. Bronchospasm is a recognised caution with acetylcysteine, which is why asthma appears in the contraindication discussion in clinical references.
Keep reading
Sources
- Zheng JP, et al. Twice daily N-acetylcysteine 600 mg for exacerbations of chronic obstructive pulmonary disease (PANTHEON): a randomised, double-blind placebo-controlled trial. Lancet Respir Med. 2014;2(3):187–194.
- Acetylcysteine. StatPearls. StatPearls Publishing.
- US Food and Drug Administration. Policy Regarding N-acetyl-L-cysteine: Guidance for Industry.
Track your dose in DoseRoutine
Log what you actually take, get reminders at the right time and check interactions against everything else in your stack.
Sign up free →